Mohit Bansal
Stock Analyst at Wells Fargo
(4.24)
# 442
Out of 5,048 analysts
172
Total ratings
65.05%
Success rate
10.46%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Overweight | $140 → $145 | $122.05 | +18.80% | 12 | Oct 31, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $580 → $615 | $642.25 | -4.24% | 19 | Oct 29, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $90 → $70 | $52.85 | +32.45% | 6 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $240 → $260 | $211.96 | +22.66% | 10 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $27 → $35 | $34.53 | +1.36% | 5 | Sep 11, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Overweight | $26 → $50 | $39.19 | +27.60% | 2 | Sep 11, 2025 | |
| MIST Milestone Pharmaceuticals | Initiates: Overweight | $4 | $1.85 | +116.22% | 1 | Sep 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $460 | $426.00 | +7.98% | 11 | Aug 6, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $170 → $150 | $103.96 | +44.29% | 2 | Aug 5, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $97 → $90 | $82.49 | +9.10% | 11 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $41.12 | +14.30% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $65 | $66.20 | -1.81% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $53 | $46.02 | +15.17% | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $1 | $1.86 | -46.24% | 4 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $970 → $1,100 | $896.53 | +22.70% | 17 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $140 | $151.44 | -7.55% | 14 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $130 → $170 | $138.38 | +22.85% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $296.30 | -5.50% | 10 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $18.22 | +64.65% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $25.94 | +169.85% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $24.66 | +21.65% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $141.96 | +19.75% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $11.78 | +15,816.81% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.99 | +1,713.60% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $11.68 | +62.67% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.37 | +4,279.56% | 4 | Dec 3, 2019 |
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $140 → $145
Current: $122.05
Upside: +18.80%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Equal-Weight
Price Target: $580 → $615
Current: $642.25
Upside: -4.24%
BioMarin Pharmaceutical
Oct 28, 2025
Maintains: Overweight
Price Target: $90 → $70
Current: $52.85
Upside: +32.45%
AbbVie
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $211.96
Upside: +22.66%
Travere Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $34.53
Upside: +1.36%
Mineralys Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $26 → $50
Current: $39.19
Upside: +27.60%
Milestone Pharmaceuticals
Sep 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.85
Upside: +116.22%
Vertex Pharmaceuticals
Aug 6, 2025
Upgrades: Overweight
Price Target: $460
Current: $426.00
Upside: +7.98%
BioNTech SE
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $103.96
Upside: +44.29%
Merck & Co.
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $97 → $90
Current: $82.49
Upside: +9.10%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $41.12
Upside: +14.30%
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $66.20
Upside: -1.81%
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $46.02
Upside: +15.17%
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $1.86
Upside: -46.24%
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $896.53
Upside: +22.70%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $151.44
Upside: -7.55%
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $138.38
Upside: +22.85%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $296.30
Upside: -5.50%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $18.22
Upside: +64.65%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $25.94
Upside: +169.85%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $24.66
Upside: +21.65%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $141.96
Upside: +19.75%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $11.78
Upside: +15,816.81%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.99
Upside: +1,713.60%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $11.68
Upside: +62.67%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.37
Upside: +4,279.56%